This panel will discuss the impact of recent Supreme Court and Federal Circuit decisions on Hatch-Waxman litigation. The panel will discuss the implications of these decisions on both innovator and generic companies.
Panel Moderator: Chandrika Vira, Director
Panelist: Lauren Rabinovic, Ph.D., Vice President and General Counsel, North Americas Generic IP, Teva Pharmaceuticals
Panelist: John Kirkland, Director of IP, Alkermes
Panelist: Dennies Varughese, Pharm.D., Director